Pura Vida Investments Increased By $545,000 Its Bio Rad Labs (Call) (BIO) Stake; Catalyst Pharmaceutical Partners (CPRX) Has 2 Sentiment

January 14, 2018 - By Hazel Jackson

Pura Vida Investments Llc increased Bio Rad Labs Inc (Call) (BIO) stake by 9.55% reported in 2017Q3 SEC filing. Pura Vida Investments Llc acquired 2,180 shares as Bio Rad Labs Inc (Call) (BIO)’s stock rose 13.43%. The Pura Vida Investments Llc holds 25,000 shares with $6.25M value, up from 22,820 last quarter. Bio Rad Labs Inc (Call) now has $7.43B valuation. The stock decreased 1.13% or $2.84 during the last trading session, reaching $248.37. About 176,339 shares traded. Bio-Rad Laboratories, Inc. (NYSE:BIO) has risen 53.78% since January 14, 2017 and is uptrending. It has outperformed by 37.08% the S&P500.

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases. The company has market cap of $401.70 million. The Company’s lead product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in second Phase III clinical trials for the treatment of patients with Lambert-Eaton Myasthenic syndrome; and is in small blinded clinical trial to treat Congenital Myasthenic syndromes, as well as is in Phase II/III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis. It currently has negative earnings. The firm also develops CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor that is in Phase Ib clinical trial for the treatment of epilepsy, infantile spams, and TouretteÂ’s disorder; and CPP-109 to treat TouretteÂ’s disorder.

Among 4 analysts covering Bio-Rad Laboratories (NYSE:BIO), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Bio-Rad Laboratories had 16 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Bio-Rad Laboratories, Inc. (NYSE:BIO) earned “Buy” rating by Jefferies on Friday, October 20. As per Friday, April 28, the company rating was maintained by Jefferies. The rating was maintained by Wells Fargo with “Buy” on Wednesday, November 29. The firm earned “Buy” rating on Wednesday, April 12 by Jefferies. Jefferies maintained Bio-Rad Laboratories, Inc. (NYSE:BIO) on Wednesday, September 7 with “Buy” rating. The stock of Bio-Rad Laboratories, Inc. (NYSE:BIO) has “Buy” rating given on Wednesday, June 28 by Deutsche Bank. CL King initiated the stock with “Buy” rating in Thursday, October 13 report. The firm has “Buy” rating by Jefferies given on Thursday, July 13. The firm earned “Buy” rating on Thursday, June 8 by Jefferies. Jefferies maintained Bio-Rad Laboratories, Inc. (NYSE:BIO) rating on Wednesday, September 27. Jefferies has “Buy” rating and $275.0 target.

Investors sentiment decreased to 0.78 in 2017 Q3. Its down 0.46, from 1.24 in 2017Q2. It dived, as 28 investors sold BIO shares while 102 reduced holdings. 37 funds opened positions while 64 raised stakes. 18.51 million shares or 2.53% more from 18.06 million shares in 2017Q2 were reported. Proshare Advsrs Limited Liability Corporation accumulated 0% or 1,777 shares. Morgan Stanley has 44,689 shares. The Illinois-based Ariel Investments Ltd Liability has invested 1.35% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Voya Investment Management Ltd holds 5,873 shares. Old Mutual Glob Investors (Uk) Ltd reported 2,533 shares stake. Beaconlight Capital Limited Liability Company holds 7.96% or 67,874 shares in its portfolio. Geode Mgmt Ltd has invested 0.01% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO). Neuberger Berman Grp Incorporated Lc, New York-based fund reported 131,393 shares. Intrepid Mgmt Inc holds 0.47% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 5,182 shares. Raymond James Services Advisors has invested 0.01% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Earnest Prtn Limited Liability invested in 114,771 shares. Leavell Inv Management invested in 0.04% or 1,300 shares. Amp Cap, Australia-based fund reported 17,280 shares. Pennsylvania-based Glenmede Com Na has invested 0% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Profund Ltd holds 2,719 shares or 0.03% of its portfolio.

Pura Vida Investments Llc decreased Globus Med Inc (NYSE:GMED) stake by 70,926 shares to 129,074 valued at $3.84 billion in 2017Q3. It also reduced Biocryst Pharmaceuticals (Call) (NASDAQ:BCRX) stake by 69,500 shares and now owns 30,500 shares. Nanostring Technologies Inc (Call) (NASDAQ:NSTG) was reduced too.

Since August 11, 2017, it had 0 insider buys, and 3 insider sales for $1.67 million activity. On Wednesday, September 13 the insider Hall Shannon sold $275,390. TSINGOS CHRISTINE A sold $1.24 million worth of stock. Crowley Michael had sold 700 shares worth $151,136.

Analysts await Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) to report earnings on March, 21. They expect $-0.06 earnings per share, down 20.00% or $0.01 from last year’s $-0.05 per share. After $-0.05 actual earnings per share reported by Catalyst Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 20.00% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Recent Posts

Twitter Auto Publish Powered By : XYZScripts.com